Mark Baker
Impact in
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Cancer therapeutics and mechanisms 2
- Epigenetics and DNA Methylation 1
-
- HIV/AIDS drug development and treatment 3
- Co-authors
- Didier Merlin (7 shared papers)Hamed Laroui (5 shared papers)Émilie Viennois (7 shared papers)Saravanan Ayyadurai (3 shared papers)Moiz A. Charania (2 shared papers)Bo Xiao (5 shared papers)Yutao Yan (2 shared papers)Fengyuan Chen (1 shared paper)
- Journals
- Open Forum Infectious Diseases (3 papers)Anti-Cancer Drugs (2 papers)Gastroenterology (1 paper)Cell Metabolism (1 paper)Biomaterials (1 paper)
- Partner nations
- United StatesChinaNew Zealand
In The Last Decade
Mark Baker
15 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 97
- Pharmaceutical Science 121
- Biomaterials 126
- Molecular Medicine 42
- Toxicology 27
- Genetics 221
Countries citing papers authored by Mark Baker
This map shows the geographic impact of Mark Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Baker more than expected).
Fields of papers citing papers by Mark Baker
This network shows the impact of papers produced by Mark Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Baker. The network helps show where Mark Baker may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Baker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 274 | |
| 2 | 2014 | 178 | |
| 3 | 2013 | 145 | |
| 4 | 2015 | 133 | |
| 5 | 2015 | 93 | |
| 6 | 2002 | 56 | |
| 7 | 2014 | 47 | |
| 8 | 2001 | 47 | |
| 9 | 2013 | 29 | |
| 10 | 2014 | 21 | |
| 11 | 2019 | 17 | |
| 12 | 2021 | 13 | |
| 13 | 2019 | 9 | |
| 14 | 2018 | 7 | |
| 15 | 2002 | 1 |
About Mark Baker
Mark Baker is a scholar working on Molecular Biology, Infectious Diseases, Oncology, Genetics and Virology, having authored 15 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (3 papers), Inflammatory Bowel Disease (3 papers), Lung Cancer Research Studies (2 papers), Cancer therapeutics and mechanisms (2 papers), HIV Research and Treatment (2 papers), Epigenetics and DNA Methylation (1 paper), Fatty Acid Research and Health (1 paper) and HIV-related health complications and treatments (1 paper). The work is most often cited by research in Pharmaceutical Science (121 citations), Biomaterials (126 citations), Molecular Medicine (42 citations), Toxicology (27 citations) and Genetics (221 citations). Mark Baker has collaborated with scholars based in United States, China and New Zealand. Frequent co-authors include Didier Merlin, Hamed Laroui, Émilie Viennois, Saravanan Ayyadurai, Moiz A. Charania, Bo Xiao, Yutao Yan, Fengyuan Chen, Shanthi V. Sitaraman and Sarah Ingersoll. Their work appears in journals such as Open Forum Infectious Diseases, Anti-Cancer Drugs, Gastroenterology, Cell Metabolism and Biomaterials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.